Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05749068 · ClinicalTrials.gov registry record · NA
Evaluation of the CapScan Device to Measure the Metabolism of Sulfasalazine
A NA study, sponsored by Envivo Bio.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
NCT05749068: Completed NA study, sponsored by Envivo Bio.
NCT05749068 is a NA study that has completed, run by Envivo Bio. The registered enrollment target is 10 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05749068, a NA study, has completed, sponsored by Envivo Bio.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
Study Summary
Evaluation of the CapScan intestinal collection device in characterizing the metabolism of sulfasalazine in the digestive tracts of healthy volunteers.
Primary Outcome
Regional measurement of sulfasalazine in the intestinal lumen, the metabolic breakdown products of sulfasalazine and the gut microbiota in the digestive tracts of healthy volunteers.
Interventions
- DEVICE CapScan intestinal sampling device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2022-09-01 |
| Est. Completion | 2022-10-30 |
| Phase | NA |
What the finished NCT05749068 record still lists
NCT05749068 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which CapScan intestinal sampling device is the first listed.
NCT05749068 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05749068 about?
NCT05749068 is a clinical study titled "Evaluation of the CapScan Device to Measure the Metabolism of Sulfasalazine". Evaluation of the CapScan intestinal collection device in characterizing the metabolism of sulfasalazine in the digestive tracts of healthy volunteers.
What is the current status of trial NCT05749068?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2022-09-01. Estimated completion is 2022-10-30.
What interventions are being tested in trial NCT05749068?
The interventions under investigation include: CapScan intestinal sampling device (DEVICE).
Who is sponsoring clinical trial NCT05749068?
This trial is sponsored by Envivo Bio, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05749068's enrollment target sits among peer trials
10 1927th of 2000 higher than 26 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI